NeuBase Therapeutics - Delisted Stock
NeuBase Therapeutics is currently unavailable and cannot be used in your analysis. The information on this page reflects the last day NeuBase Therapeutics was actively traded.
Valuation
Check how we calculate scores
NeuBase Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. NeuBase Therapeutics market risk premium is the additional return an investor will receive from holding NeuBase Therapeutics long position in a well-diversified portfolio.
Mean Deviation | 4.27 | |||
Standard Deviation | 6.12 | |||
Variance | 37.5 | |||
Risk Adjusted Performance | (0.12) |
View NeuBase Therapeutics Related Equities
Risk & Return | Correlation |
NeuBase Therapeutics Corporate Management
Curt Bradshaw | Chief Officer | Profile | |
Robert Zamboni | Chief Board | Profile | |
Alan JD | G Counsel | Profile | |
Ron MBA | Sr Devel | Profile | |
Shannon McCarthy | Chief Officer | Profile |
Still Interested in NeuBase Therapeutics?
Investing in delisted delisted stocks can be risky, as the stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |